ADRENALIN (epinephrine in sodium chloride) by Pfizer is adrenergic alpha-agonists [moa]. First approved in 2023.
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
ADRENALIN is an intravenous solution of epinephrine in sodium chloride, an alpha-adrenergic agonist approved by the FDA in April 2023. It is indicated for acute hemodynamic support in critical care settings where rapid sympathomimetic action is required. The drug works by binding to adrenergic receptors, triggering vasoconstriction and increased cardiac output.
Early-stage peak lifecycle suggests growing commercial infrastructure and brand team investment, though scale remains modest relative to legacy epinephrine products.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis
Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection
Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline
Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext
Worked on ADRENALIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ADRENALIN offers stability within a niche acute care segment backed by Pfizer's scale and distribution, though the modest commercial footprint (2,074 Part D claims in 2023) suggests a smaller brand team and limited promotional investment compared to primary care products. Career growth is driven by market penetration, formulary conversion, and hospital account management rather than indication expansion or external development activity.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo